Performance of Spectral CT-scan in Patients With Metastatic Colorectal Cancer: a Prospective Multicentre Study

NCT06024837 | Recruiting

• 1 other identifier: IRBN1162022/CHUSTE
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Spectral CT is a rapidly expanding imaging modality that allows a reduction in iodine dose and irradiation compared to conventional scanning. It uses the difference in attenuation of the material according to the two different energy levels of the incident x-ray beams. The dual-energy scanner has a wide range of clinical applications, particularly in abdominal imaging.

Conditions

Colo-rectal Cancer

Keywords

Colo-rectal cancer; spectral CT scan; liver metastases; peritoneal carcinosis

Outcome Measures

Primary Outcomes (2)

• Comparison of peritoneal lesion mapping between spectral scanning and conventional scanning

  Comparison of peritoneal lesion mapping between spectral scanning (monoenergetic acquisitions, iodine mapping, etc.) and conventional scanning (acquisition obtained during spectral acquisition).

  Year : 1

• Comparison of hepatic lesion mapping between spectral scanning and conventional scanning

  Comparison of hepatic lesion mapping between spectral scanning (monoenergetic acquisitions, iodine mapping, etc.) and conventional scanning (acquisition obtained during spectral acquisition).

  Year : 1

Secondary Outcomes (2)

• Evaluation of response to chemotherapy in RECIST 1.1

  Year : 1

• Evaluation of response to chemotherapy in Radiomics

  Year : 1

Study Arms (1)

Patients with Colo-rectal Cancer

Patients with Colo-rectal Cancer will be included.

Other: CT Images

Interventions

CT Images OTHER

Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer

Patients with Colo-rectal Cancer

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with synchronous or metachronous peritoneal and/or liver metastases of colorectal cancer with curative surgical plans.

You may qualify if:

• Patients followed for colorectal cancer with synchronous or metachronous liver metastases and/or peritoneal carcinosis
• Patients with a curative surgical resection plan

You may not qualify if:

• Patients with non-metastatic colorectal cancer
• Patients treated with chemotherapy without surgical plans
• Patients with colorectal cancer with extra-hepatic and extra-peritoneal metastases alone (e.g. lung, bone)

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Saint Etienne: lead

Study Sites (1)

CHU Saint-Etienne

Saint-Etienne, 42000, France

RECRUITING

MeSH Terms

Conditions

Colonic Neoplasms

Condition Hierarchy (Ancestors)

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases

Study Officials

• Rémi GRANGE, MD

  CHU SAINT-ETIENNE

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Rémi GRANGE, MD

CONTACT

(0)477828963; remi.grange@chu-st-etienne.fr

Sylvain GRANGE, MD

CONTACT

(0)477829066; sylvain.grange@chu-st-etienne.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 21, 2023
• First Posted: September 6, 2023
• Study Start: June 7, 2023
• Primary Completion: January 1, 2025
• Study Completion: June 1, 2025
• Last Updated: September 20, 2024

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)